A5026247885- Peroxisome Proliferator-Activated Receptors
- Eicosanoids and Hypertension Pharmacology
- Cancer, Lipids, and Metabolism
- Melanoma and MAPK Pathways
- Cancer, Hypoxia, and Metabolism
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Diet, Metabolism, and Disease
- Immunotherapy and Immune Responses
- Cancer Mechanisms and Therapy
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Cannabis and Cannabinoid Research
- Protein Degradation and Inhibitors
- Brain Metastases and Treatment
- Neurological Disease Mechanisms and Treatments
- Hedgehog Signaling Pathway Studies
- Epigenetics and DNA Methylation
- Innovations in Medical Education
- Telomeres, Telomerase, and Senescence
- Diversity and Career in Medicine
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Advances in Oncology and Radiotherapy
The Wistar Institute
2015-2022
New York Institute of Technology
2020-2021
Providence Portland Medical Center
2020
Temple University
2015
Morehouse School of Medicine
2009
McGill University
1994-2004
Montreal General Hospital
1994
Royal Victoria Regional Health Centre
1994
Royal Victoria Hospital
1994
Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification this heterogeneous cancer, several targeted immune therapies were approved increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) live tissue samples from 384 patients representing the full spectrum clinical, therapeutic, mutational, heterogeneity melanoma. PDX been...
Abstract Brain metastasis, the most lethal form of melanoma and carcinoma, is consequence favorable interactions between invading cancer cells brain cells. Peroxisome proliferator–activated receptor γ (PPARγ) has ambiguous functions in development, its relevance advanced metastasis remains unclear. Here, we demonstrate that astrocytes, unique glial cells, activate PPARγ metastatic activation enhances cell proliferation outgrowth brain. Mechanistically, astrocytes have a high content...
Mutant forms of p53 protein often possess protumorigenic functions, conferring increased survival and migration to tumor cells via their “gain-of-function” activity. Whether how a common polymorphism in TP53 at amino acid 72 (Pro72Arg; referred here as P72 R72) impacts this gain function has not been determined. We show that mutant enhances metastasis tumors through the ability bind regulate PGC-1α regulation is markedly impacted by codon polymorphism. Tumor with R72 variant along greatly...
// Batool Shannan 1, 2 , Andrea Watters 1 Quan Chen Stefan Mollin 3 Markus Dörr Eric Meggers Xiaowei Xu 4 Phyllis A. Gimotty 5 Michela Perego Ling Li Joseph Benci Clemens Krepler Patricia Brafford Jie Zhang 6 Zhi Wei Gao Qin Liu Xiangfan Yin Katherine L. Nathanson Meenhard Herlyn * Adina Vultur Program of Cellular and Molecular Oncogenesis, Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA Department Dermatology, University Hospital Essen, Germany Chemistry, Marburg,...
There has been interest in the literature possible existence of a gene that predisposes to both breast cancer (BC) and colorectal (CRC). We describe detailed characterisation one kindred, MON1080, with 10 cases BC or CRC invasive among 26 first-, second- third-degree relatives. Linkage analysis suggested mutation was present BRCA2. DNA sequencing from III: 22 (diagnosed lobular BC) identified BRCA2 exon 3 542G>T (L105X) mutation. Her sister (III: 25) had endometrial carries same Following...
Recent reports indicate that neural stem cells (NSCs) exist in a cluster-like formation close proximity to cerebral microvessels. Similar appearing clusters can be seen ex vivo NSC cultures termed neurospheres. It is known this neurosphere configuration important for preserving stemness and proliferative state. How NSCs form neurospheres or neuroclusters remains largely undetermined. In study, we show primary human express the tight junction proteins (TJPs): zonula occludens-1 (ZO-1),...
Summary Targeted therapies for mutant BRAF metastatic melanoma are effective but not curative due to acquisition of resistance. PI 3K signaling is a common mediator therapy resistance in melanoma; thus, the need inhibitors critical. However, testing adherent cultures always reflective their potential vivo. To emphasize this, we compared different specificity two‐ and three‐dimensional (2D, 3D) models show that drug response predictions gain from evaluation using 3D models. Our results...
The upregulation of the adaptor protein NUMB triggers melanocytic differentiation from multipotent skin stem cells, which share many properties with aggressive melanoma cells. Although acts as a tumor suppressor in various human cancer types, little is known about its role melanoma. In this study, we investigated progression and regulatory mechanism. Analysis Cancer Genome Atlas datasets revealed that high expression tissues correlates improved patient survival. Moreover, downregulated...
Melanoma, the deadliest of skin cancers, has a high propensity to form brain metastases that are associated with markedly worsened prognosis. In spite recent therapeutic advances, melanoma lesions remain clinical challenge, biomarkers predicting dissemination not clear and differences other metastatic sites poorly understood.We examined genetically diverse panel human-derived metastasis (MBM) extracranial cell lines using targeted sequencing, Reverse Phase Protein Array, protein expression...
Abstract #3071 Background: We have previously reported that in vitro and vivo leptin signaling mediates proliferation of mouse 4T1 mammary tumor (MT) cells levels VEGF VEGFR2. Therefore, we hypothesize can contribute to MT growth by augmenting angiogenesis through the regulation expression. To test this assessed whether regulates promoter activity if leptin-induced factors (HIF-1α, NFκB, AP1, SP1) regulate promoter. Materials Methods: Mouse (4T1, EM6 MMT) were transiently transfected with...
Abstract Current treatments against malignant melanoma, including the use of small molecule inhibitors, are displaying encouraging results in clinic. However, tumor resistance develops even for patients who initially respond favorably. To identify novel drug targets and compounds with anti-melanoma activity, we screened a panel genetically distinct human-derived metastatic melanoma cell lines structurally diverse organometallic kinase inhibitors. We observed compound that preferentially...
<p>Figure S3 shows WM4265.2 and two BrM cells response to staurosporine-induced cell death at similar level.</p>
<p>Figure S4 shows gene set variation analyses (GSVA) of PPAR and EIF2 pathways in WM4265.2-BrMs.</p>
<p>Figure S6 shows exogenous AA, but not DHA promotes the growth of BrM cells.</p>
<p>Figure S2 shows astrocytes facilitate the growth and survival of brain metastatic cancer cells.</p>
<p>Figure S1 shows the generation of brain metastasis models.</p>
<p>Figure S5 shows PPAR pathway is activated in MDA231-BrM and Yumm1.7-BrM cells further enhanced by astrocyte co-culture.</p>